Stock analysis, AI verdict, fundamentals & technical signals
Rating: NEUTRAL
Price: $1.37 Analyst target: $8.56 Upside: 524.82%
Equillium, Inc., a clinical-stage biotechnology company, develops and sells products to treat severe autoimmune and inflammatory or immuno-inflammatory disorders with unmet medical needs. The company is headquartered in La Jolla, California.
See the full interactive analysis & chart →Informational only — not investment advice.